TY - JOUR
T1 - Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era
AU - McNamara, Mairéad G.
AU - Lwin, Zarnie
AU - Jiang, Haiyan
AU - Chung, Caroline
AU - Millar, Barbara Ann
AU - Sahgal, Arjun
AU - Laperriere, Normand
AU - Mason, Warren P.
N1 - Funding Information:
Acknowledgments We thank Princess Margaret Cancer Centre Cancer Registry. Dr. Mairéad G. McNamara is funded by the Princess Cancer Centre clinical fellowship fund. All other authors have no funding to declare.
PY - 2014/3
Y1 - 2014/3
N2 - With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14.6 months. This is not as informative to patients who have survived for some time. Conditional probability of survival may offer more relevant survival estimates. Outcomes/conditional probability of survival and post-progression survival (PPS) estimates were retrospectively reviewed in the TMZ treatment era of 882 consecutive patients with a diagnosis of GBM from January 2004 to August 2010. Median age of entire cohort was 62 years including 62 % males. Baseline performance status (PS) was 0-1 in 67, 23 % had frontal lobe tumors, 58 % received concurrent RT/TMZ ± adjuvant TMZ. Survival (OS) was similar for those with frontal lobe tumors versus other locations (P = 0.25). OS for patients receiving standard RT/TMZ ± TMZ was 14.2 months. Age, PS, extent of surgery, therapy post-surgery had significant effects on OS. OS for entire cohort at 1, 2, 3, 4, 5 years was 43.4, 17.9, 10.4, 8.4, 7.2 % respectively. Conditional probability of survival of an additional year given survival to 1, 2, 3, 4, 5 years was 41.4, 58, 80.7, 85.7, 81.5 % respectively. Conditional probability of survival for those patients receiving concurrent RT/TMZ ± adjuvant TMZ was similar. Patients who progress >18 months after their initial treatment for GBM had significantly greater 2 and 5 year PPS as well as OS. Conditional probabilities of survival may provide more meaningful life expectancy predictions for survivors of GBM than conventional survival outcomes.
AB - With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14.6 months. This is not as informative to patients who have survived for some time. Conditional probability of survival may offer more relevant survival estimates. Outcomes/conditional probability of survival and post-progression survival (PPS) estimates were retrospectively reviewed in the TMZ treatment era of 882 consecutive patients with a diagnosis of GBM from January 2004 to August 2010. Median age of entire cohort was 62 years including 62 % males. Baseline performance status (PS) was 0-1 in 67, 23 % had frontal lobe tumors, 58 % received concurrent RT/TMZ ± adjuvant TMZ. Survival (OS) was similar for those with frontal lobe tumors versus other locations (P = 0.25). OS for patients receiving standard RT/TMZ ± TMZ was 14.2 months. Age, PS, extent of surgery, therapy post-surgery had significant effects on OS. OS for entire cohort at 1, 2, 3, 4, 5 years was 43.4, 17.9, 10.4, 8.4, 7.2 % respectively. Conditional probability of survival of an additional year given survival to 1, 2, 3, 4, 5 years was 41.4, 58, 80.7, 85.7, 81.5 % respectively. Conditional probability of survival for those patients receiving concurrent RT/TMZ ± adjuvant TMZ was similar. Patients who progress >18 months after their initial treatment for GBM had significantly greater 2 and 5 year PPS as well as OS. Conditional probabilities of survival may provide more meaningful life expectancy predictions for survivors of GBM than conventional survival outcomes.
KW - Conditional probability of survival
KW - Frontal lobe tumor
KW - Glioblastoma
KW - Overall survival
KW - Post-progression survival
KW - Temozolomide
UR - http://www.scopus.com/inward/record.url?scp=84901632623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901632623&partnerID=8YFLogxK
U2 - 10.1007/s11060-014-1368-7
DO - 10.1007/s11060-014-1368-7
M3 - Article
C2 - 24469855
AN - SCOPUS:84901632623
SN - 0167-594X
VL - 117
SP - 153
EP - 160
JO - Journal of neuro-oncology
JF - Journal of neuro-oncology
IS - 1
ER -